TY - JOUR
T1 - Intragastric balloon for obesity treatment
T2 - results of a multicentric evaluation for balloons left in place for more than 6 months
AU - Alfredo, Genco
AU - Roberta, Maselli
AU - Francesca, Frangella
AU - Massimiliano, Cipriano
AU - Pietro, Forestieri
AU - Daniela, Delle Piane
AU - Francesco, Furbetta
AU - Giancarlo, Micheletto
AU - Franco, Ciampaglia
AU - Paola, Granelli
AU - Maurizio, Zilli
AU - Michele, Lorenzo
AU - Giorgio, Di Rocco
AU - Domenico, Giannotti
AU - Adriano, Redler
PY - 2015/8/25
Y1 - 2015/8/25
N2 - Background: Obesity is a major risk factor for several chronic diseases. The BioEnterics® Intragastric Balloon (BIB®) is used worldwide as a short-term (6 months) treatment in morbid obese patients. However, removal of BIB® past 6 months is a common occurrence in clinical practice often as a result of patient factors. The aim of the present Italian multicentre cohort study was to evaluate the safety and efficacy of the BIB® left in situ for more than 6 months. Materials and methods: A total of eight Italian centres participated in the study. Participating centres received a standardised questionnaire designed to capture safety and efficacy data. Weight loss data, as well as date, and reason for removal of the BIB® after 6 months were recorded. Adverse events, including mortality and complications, operators’ subjective technical notes and findings, and difficulties during removal procedure were also collected. Results: Six hundred and eleven patients were included. In the majority of cases, patient extended BIB® treatment due to satisfactory weight loss (44 %). At 6 months, all patients achieved a BMI statistically lower than the initial BMI (p ® use up to 14 months safely maintains weight loss and satiety with greater results than that up to 6 months, without complications.
AB - Background: Obesity is a major risk factor for several chronic diseases. The BioEnterics® Intragastric Balloon (BIB®) is used worldwide as a short-term (6 months) treatment in morbid obese patients. However, removal of BIB® past 6 months is a common occurrence in clinical practice often as a result of patient factors. The aim of the present Italian multicentre cohort study was to evaluate the safety and efficacy of the BIB® left in situ for more than 6 months. Materials and methods: A total of eight Italian centres participated in the study. Participating centres received a standardised questionnaire designed to capture safety and efficacy data. Weight loss data, as well as date, and reason for removal of the BIB® after 6 months were recorded. Adverse events, including mortality and complications, operators’ subjective technical notes and findings, and difficulties during removal procedure were also collected. Results: Six hundred and eleven patients were included. In the majority of cases, patient extended BIB® treatment due to satisfactory weight loss (44 %). At 6 months, all patients achieved a BMI statistically lower than the initial BMI (p ® use up to 14 months safely maintains weight loss and satiety with greater results than that up to 6 months, without complications.
KW - BIB
KW - Intragastric balloon
KW - Obesity management
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=84937912030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937912030&partnerID=8YFLogxK
U2 - 10.1007/s00464-014-3957-0
DO - 10.1007/s00464-014-3957-0
M3 - Article
C2 - 25480604
AN - SCOPUS:84937912030
VL - 29
SP - 2339
EP - 2343
JO - Surgical Endoscopy
JF - Surgical Endoscopy
SN - 0930-2794
IS - 8
ER -